The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies

被引:45
|
作者
Muz, Barbara [1 ]
de la Puente, Pilar [1 ]
Azab, Feda [1 ]
Luderer, Micah [1 ]
Azab, Abdel Kareem [1 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA
关键词
MULTIPLE-MYELOMA CELLS; BONE-MARROW MICROENVIRONMENT; HEMATOPOIETIC STEM-CELLS; ACTIVATED PRODRUG TH-302; NF-KAPPA-B; INDUCIBLE FACTOR-1-ALPHA; IN-VIVO; HODGKIN-LYMPHOMA; LEUKEMIC-CELLS; SOLID TUMORS;
D O I
10.1158/1541-7786.MCR-14-0028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor hypoxia is a well-described phenomenon during the progression of solid tumors affecting cell signaling pathways and cell metabolism; however, its role in hematologic malignancies has not been given the same attention in the literature. Therefore, this review focuses on the comparative differences between solid and hematologic malignancies with emphasis on the role of hypoxia during tumorigenesis and progression. In addition, contribution of the bone marrow and angiogenic environment are also discussed. Insight is provided into the role of hypoxia in metastatic spread, stemness, and drug resistance in hematologic conditions. Finally, emerging therapeutic strategies such as small-molecule prodrugs and hypoxia-inducible factor (HIF) targeting approaches are outlined to combat hypoxic cells and/or adaptive mechanisms in the treatment of hematologic malignancies. (C) 2014 AACR.
引用
收藏
页码:1347 / 1354
页数:8
相关论文
共 50 条
  • [11] Current Role of Genetics in Hematologic Malignancies
    Prakash, Gaurav
    Kaur, Anupriya
    Malhotra, Pankaj
    Khadwal, Alka
    Sharma, Prashant
    Suri, Vikas
    Varma, Neelam
    Varma, Subhash
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 (01) : 18 - 31
  • [12] Update on the role of copanlisib in hematologic malignancies
    Le, Thuy
    Jeret, David
    Bryan, Locke J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [13] Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies
    Testa, Ugo
    Castelli, Germana
    Pelosi, Elvira
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
  • [14] Role of the ubiquitin proteasome system in hematologic malignancies
    Sahasrabuddhe, Anagh A.
    Elenitoba-Johnson, Kojo S. J.
    IMMUNOLOGICAL REVIEWS, 2015, 263 (01) : 224 - 239
  • [15] The emerging role of angiogenesis inhibitors in hematologic malignancies
    Giles, FJ
    ONCOLOGY-NEW YORK, 2002, 16 (05): : 23 - 29
  • [16] Evolving role of radiation therapy for hematologic malignancies
    Lee, Chung K.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (02) : 471 - +
  • [17] Role of SIRT1 in hematologic malignancies
    Huang, Fei-teng
    Sun, Jie
    Zhang, Lei
    He, Xin
    Zhu, Ying-hui
    Dong, Hao-jie
    Wang, Han-ying
    Zhu, Lei
    Zou, Jing-ying
    Huang, Jin-wen
    Li, Ling
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2019, 20 (05): : 391 - 398
  • [18] The Role of Radiation Therapy for Palliation of Hematologic Malignancies
    Yang, Joanna C.
    SEMINARS IN RADIATION ONCOLOGY, 2025, 35 (01) : 11 - 15
  • [19] The evolving role of lenalidomide in the treatment of hematologic malignancies
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 497 - 509
  • [20] Role of transforming growth factor-β in hematologic malignancies
    Dong, Mei
    Blobe, Gerard C.
    BLOOD, 2006, 107 (12) : 4589 - 4596